As you may or may not know biotech company InterMune is up over 100% today on massive volume.. The catalyst: InterMune announces positive opinion for approval of Esbriet in EU... So lets take a look at the upgrade party in the order listed....

1. InterMune upgraded to Buy from Hold at Canaccord
2. nterMune upgraded to Outperform from Market Perform at JMP Securities target 35
3. InterMune upgraded to Outperform from Neutral at WedbushPrice target raised to $55
4. InterMune upgraded to Outperform from Perform at OppenheimerPrice target $41